Featured

Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease



Published
To cite: David MCB, Del Giovane M, Liu KY, et al. Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery & Psychiatry Published Online First: 05 July 2022. doi: 10.1136/jnnp-2022-329136
Read the full article here: http://dx.doi.org/10.1136/jnnp-2022-329136
Objective: To assess the efficacy of drugs with principally noradrenergic action in improving cognitive and europsychiatric symptoms in Alzheimer’s disease.
Conclusions: Repurposing of established noradrenergic drugs is most likely to offer effective treatment in Alzheimer’s disease for general cognition and apathy. However, several factors should be considered before designing future clinical trials. These include targeting of appropriate patient subgroups and understanding the dose effects of individual drugs and their interactions with other treatments to minimise risks and maximise therapeutic effects.
Category
Health
Be the first to comment